International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(8), P. 7640 - 7640
Published: April 21, 2023
Hepatocellular
carcinoma
(HCC)
has
one
of
the
highest
mortality
rates
among
solid
cancers.
Late
diagnosis
and
a
lack
efficacious
treatment
options
contribute
to
dismal
prognosis
HCC.
Immune
checkpoint
inhibitor
(ICI)-based
immunotherapy
presented
new
milestone
in
cancer.
Immunotherapy
yielded
remarkable
responses
range
cancer
types
including
Based
on
therapeutic
effect
ICI
alone
(programmed
cell
death
(PD)-1/programmed
death-ligand1
(PD-L)1
antibody),
investigators
have
developed
combined
therapies
+
ICI,
tyrosine
kinase
(TKI),
locoregional
or
novel
immunotherapy.
Although
these
regimens
demonstrated
increasing
efficacy
with
addition
drugs,
development
biomarkers
predict
toxicity
response
patients
receiving
is
urgent
need.
PD-L1
expression
tumor
cells
received
most
attention
early
studies
various
predictive
biomarkers.
However,
limited
utility
as
biomarker
Accordingly,
subsequent
evaluated
mutational
burden
(TMB),
gene
signatures,
multiplex
immunohistochemistry
(IHC)
In
this
review,
we
aim
discuss
current
state
for
HCC,
results
studies,
future
direction.
The Oncologist,
Journal Year:
2024,
Volume and Issue:
29(5), P. e635 - e642
Published: March 2, 2024
Abstract
Background
Our
previous
work
indicated
that
the
addition
of
lobaplatin
to
combined
therapy
with
taxane
and
anthracycline
can
improve
pathological
complete
response
rate
neoadjuvant
for
triple-negative
breast
cancer
(TNBC)
lengthen
long-term
survival
significantly,
but
therapeutic
markers
this
regimen
are
unclear.
Methods
Eighty-three
patients
who
met
inclusion
criteria
were
included
in
post
hoc
analysis.
We
analyzed
association
between
platelet-to-lymphocyte
ratio
(PLR)
neutrophil-to-lymphocyte
(NLR)
before
chemotherapy
efficacy
prognosis
after
treatment
docetaxel,
epirubicin,
regimen.
χ2
test
Cox
regression
used
analyze
PLR
NLR
total
pathologic
(tpCR),
as
well
event-free
(EFS)
overall
(OS),
respectively.
Results
The
tpCR
PLR−
group
was
49.0%
(25/51),
which
significantly
higher
than
PLR+
(25.0%
[8/32],
P
=
.032).
NLR−
49.1%
(26/53),
NLR+
(23.3%
[7/30],
.024).
PLR−NLR−
(PLR−
NLR−)
53.7%
(22/41),
PLR+/NLR+
(PLR+
or/and
NLR+)
(26.1%
[11/42];
.012).
EFS
OS
shorter
those
(P
.028
EFS;
.047
OS).
Patients
had
a
longer
.002).
Conclusion
could
be
predict
taxane,
anthracycline,
TNBC,
lower
values
better
prognosis.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(8), P. 4243 - 4243
Published: April 11, 2024
Melanoma
is
the
leading
cause
of
global
skin
cancer-related
death
and
currently
ranks
as
third
most
commonly
diagnosed
cancer
in
Australia.
patients
with
in-transit
metastases
(ITM),
a
type
locoregional
metastasis
located
close
to
primary
tumor
site,
exhibit
high
likelihood
further
disease
progression
poor
survival
outcomes.
Immunotherapies,
particularly
immune
checkpoint
inhibitors
(ICI),
have
demonstrated
remarkable
efficacy
ITM
reduced
occurrence
prolonged
survival.
The
major
challenge
immunotherapeutic
lies
limited
understanding
melanoma
biology,
hindering
our
ability
identify
who
likely
respond
ICIs
effectively.
In
this
review,
we
provided
an
overview
disease.
We
outlined
key
ICI
therapies
critical
features
associated
therapy
response
or
resistance.
Lastly,
dissected
underlying
biological
components,
including
cellular
compositions
their
communication
networks
within
compartment,
enhance
interactions
between
immunotherapy
melanoma,
providing
insights
for
future
investigation
development
drug
targets
predictive
biomarkers.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1727 - 1727
Published: April 29, 2024
The
tumor
microenvironment
(TME),
a
complex
assembly
of
cellular
and
extracellular
matrix
(ECM)
components,
plays
crucial
role
in
driving
progression,
shaping
treatment
responses,
influencing
metastasis.
This
narrative
review
focuses
on
the
cutaneous
squamous
cell
carcinoma
(cSCC)
stroma,
highlighting
its
key
constituents
their
dynamic
contributions.
We
examine
how
significant
changes
within
cSCC
ECM—specifically,
alterations
fibronectin,
hyaluronic
acid,
laminins,
proteoglycans,
collagens—promote
cancer
metastasis,
drug
resistance.
composition
TME
is
also
explored,
detailing
intricate
interplay
cancer-associated
fibroblasts
(CAFs),
mesenchymal
stem
cells
(MSCs),
endothelial
cells,
pericytes,
adipocytes,
various
immune
populations.
These
diverse
players
modulate
development,
angiogenesis,
responses.
Finally,
we
emphasize
TME’s
potential
as
therapeutic
target.
Emerging
strategies
discussed
this
include
harnessing
system
(adoptive
transfer,
checkpoint
blockade),
hindering
disrupting
CAF
activity,
manipulating
ECM
components.
approaches
underscore
vital
that
deciphering
interactions
advancing
therapy.
Further
research
illuminating
these
relationships
will
uncover
new
avenues
for
developing
more
effective
treatments
cSCC.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(11), P. 2027 - 2027
Published: May 27, 2024
Endometrial
cancer
is
one
the
most
prevalent
gynecological
cancers
and,
unfortunately,
has
a
poor
prognosis
due
to
low
response
rates
traditional
treatments.
However,
progress
in
molecular
biology
and
understanding
genetic
mechanisms
involved
tumor
processes
offers
valuable
information
that
led
current
classification
describes
four
subtypes
of
endometrial
cancer.
This
review
focuses
on
pathogenesis
cancers,
such
as
mutations,
defects
DNA
mismatch
repair
pathway,
epigenetic
changes,
or
dysregulation
angiogenic
hormonal
signaling
pathways.
The
preclinical
genomic
investigations
presented
allowed
for
identification
some
molecules
could
be
used
biomarkers
diagnose,
predict,
monitor
progression
Besides
therapies
known
clinical
practice,
targeted
therapy
described
new
treatment
involves
identifying
specific
targets
cells.
By
selectively
inhibiting
these
targets,
key
pathways
can
disrupted
while
normal
cells
are
protected.
connection
between
vital
fight
against
Ongoing
research
trials
exploring
use
standard
agents
combination
with
other
strategies
like
immunotherapy
anti-angiogenesis
improve
outcomes
personalize
patients
approach
potential
transform
management
patients.
In
conclusion,
enhancing
tools
essential
stratifying
risk
guiding
surgery,
adjuvant
therapy,
women
addition,
from
this
may
have
an
value
personalized
patient’s
life.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(8), P. 7640 - 7640
Published: April 21, 2023
Hepatocellular
carcinoma
(HCC)
has
one
of
the
highest
mortality
rates
among
solid
cancers.
Late
diagnosis
and
a
lack
efficacious
treatment
options
contribute
to
dismal
prognosis
HCC.
Immune
checkpoint
inhibitor
(ICI)-based
immunotherapy
presented
new
milestone
in
cancer.
Immunotherapy
yielded
remarkable
responses
range
cancer
types
including
Based
on
therapeutic
effect
ICI
alone
(programmed
cell
death
(PD)-1/programmed
death-ligand1
(PD-L)1
antibody),
investigators
have
developed
combined
therapies
+
ICI,
tyrosine
kinase
(TKI),
locoregional
or
novel
immunotherapy.
Although
these
regimens
demonstrated
increasing
efficacy
with
addition
drugs,
development
biomarkers
predict
toxicity
response
patients
receiving
is
urgent
need.
PD-L1
expression
tumor
cells
received
most
attention
early
studies
various
predictive
biomarkers.
However,
limited
utility
as
biomarker
Accordingly,
subsequent
evaluated
mutational
burden
(TMB),
gene
signatures,
multiplex
immunohistochemistry
(IHC)
In
this
review,
we
aim
discuss
current
state
for
HCC,
results
studies,
future
direction.
